diffuse cutaneous scleroderma
GPTKB entity
Statements (39)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
autoimmune disease
subtype of systemic sclerosis |
| gptkbp:affects |
gptkb:skin
internal organs |
| gptkbp:associatedWith |
gptkb:Raynaud's_phenomenon
pulmonary fibrosis cardiac involvement gastrointestinal involvement renal crisis |
| gptkbp:causedBy |
unknown
|
| gptkbp:characterizedBy |
early visceral involvement
rapid progression widespread skin thickening |
| gptkbp:diagnosedBy |
clinical examination
skin biopsy autoantibody testing |
| gptkbp:distinctiveFeature |
gptkb:limited_cutaneous_scleroderma
|
| gptkbp:firstDescribed |
20th century
|
| gptkbp:hasAutoantibody |
anti-Scl-70 (anti-topoisomerase I)
antinuclear antibody (ANA) |
| https://www.w3.org/2000/01/rdf-schema#label |
diffuse cutaneous scleroderma
|
| gptkbp:ICD-10_code |
M34.0
|
| gptkbp:partOf |
systemic sclerosis spectrum
|
| gptkbp:prognosis |
variable
worse than limited cutaneous scleroderma |
| gptkbp:riskFactor |
female sex
age 30-50 |
| gptkbp:symptom |
fatigue
joint pain difficulty swallowing shortness of breath skin tightening swelling of hands and feet |
| gptkbp:treatment |
physical therapy
immunosuppressive therapy corticosteroids organ-specific management |
| gptkbp:bfsParent |
gptkb:Scleroderma
|
| gptkbp:bfsLayer |
7
|